Edwards Lifesciences Co. (NYSE:EW) Holdings Decreased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its position in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 0.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 806,466 shares of the medical research company’s stock after selling 448 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 0.13% of Edwards Lifesciences worth $66,639,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Parkman Healthcare Partners LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $6,768,000. Petrus Trust Company LTA bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $201,000. Quadrature Capital Ltd increased its holdings in shares of Edwards Lifesciences by 62.1% in the 3rd quarter. Quadrature Capital Ltd now owns 41,649 shares of the medical research company’s stock valued at $3,445,000 after acquiring an additional 15,963 shares during the last quarter. Quantamental Technologies LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $1,413,000. Finally, Lido Advisors LLC boosted its position in Edwards Lifesciences by 2.7% during the 3rd quarter. Lido Advisors LLC now owns 7,411 shares of the medical research company’s stock valued at $612,000 after purchasing an additional 198 shares during the period. 80.35% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 3.1 %

Shares of Edwards Lifesciences stock opened at $76.62 on Tuesday. The stock’s fifty day moving average is $78.00 and its 200-day moving average is $79.61. The firm has a market capitalization of $46.61 billion, a PE ratio of 31.40, a price-to-earnings-growth ratio of 4.33 and a beta of 1.01. The company has a quick ratio of 2.17, a current ratio of 3.03 and a debt-to-equity ratio of 0.10. Edwards Lifesciences Co. has a 12-month low of $67.13 and a 12-month high of $131.10.

Edwards Lifesciences (NYSE:EW – Get Rating) last announced its earnings results on Tuesday, January 31st. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Edwards Lifesciences had a return on equity of 26.05% and a net margin of 28.27%. Edwards Lifesciences’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.51 earnings per share. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.52 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, CEO Michael A. Mussallem sold 19,875 shares of the business’s stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $76.39, for a total transaction of $1,518,251.25. Following the sale, the chief executive officer now directly owns 157,353 shares of the company’s stock, valued at $12,020,195.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Jean-Luc M. Lemercier sold 6,640 shares of the company’s stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $76.96, for a total transaction of $511,014.40. Following the transaction, the vice president now directly owns 168,875 shares of the company’s stock, valued at $12,996,620. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction on Wednesday, December 14th. The shares were sold at an average price of $76.39, for a total value of $1,518,251.25. Following the transaction, the chief executive officer now directly owns 157,353 shares in the company, valued at $12,020,195.67. The disclosure for this sale can be found here. Insiders have sold 101,386 shares of company stock valued at $7,834,077 over the last three months. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on EW. Royal Bank of Canada reduced their price objective on Edwards Lifesciences from $118.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, November 28th. Raymond James lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Monday, February 6th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, January 6th. Wolfe Research lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 1st. Finally, Canaccord Genuity Group reduced their price target on Edwards Lifesciences from $78.00 to $73.00 and set a “hold” rating for the company in a research report on Monday, December 12th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus price target of $88.95.

Edwards Lifesciences Profile

(Get Rating)

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.